Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.40 |
| ▸ | PKM | P14618 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1522738 | 0.79 | PKM (0.41) | PTGS1PTGS2PKMCA2CA12 | |
| SCHEMBL669663 | 0.79 | CA1 (0.44) | PTGS1PTGS2PKMCA2CA12 | |
| SCHEMBL2929807 | 0.79 | CA2 (0.41) | PTGS1PTGS2CA2CA12CA9 | |
| SCHEMBL3732613 | 0.79 | LMNA (0.37) | ALDH1A1TSHRMAPK1HSD17B10CYP3A4 | |
| SCHEMBL3600104 | 0.77 | CA2 (0.46) | CA2CA12CA9CA1ALDH1A1 | |
| SCHEMBL31536843 | 0.77 | CA2 (0.46) | CA2CA12CA9CA1ALDH1A1 | |
| SCHEMBL29381119 | 0.77 | NMT1 (0.49) | PTGS1PTGS2PKMCA2CA12 | |
| SCHEMBL114242 | 0.77 | NMT1 (0.49) | PTGS1PTGS2PKMCA2CA12 | |
| SCHEMBL691733 | 0.74 | ALDH1A1 (0.56) | PKMCA2CA12CA9CA1 | |
| SCHEMBL29469851 | 0.74 | PTGS1 (0.42) | PTGS1PTGS2PKMCA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12084415-B2 | Biomolecule-polymer-pharmaceutical agent conjugates for delivering the pharmaceutical agent | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-09-10 | — | — | US | disclosed |
| US-20230192610-A1 | BIOMOLECULE-POLYMER-PHARMACEUTICAL AGENT CONJUGATES FOR DELIVERING THE PHARMACEUTICAL AGENT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2023-06-22 | — | — | US | disclosed |
| EP-3052520-A2 | STABILIZED POLYPEPTIDES AND USES THEREOF | President and Fellows of Harvard College (US) | 2016-08-10 | — | — | EP | disclosed |
| EP-3003314-A2 | NOVEL COMPOUNDS AND USES THEREOF | Kala Pharmaceuticals, Inc. (US) | 2016-04-13 | — | — | EP | disclosed |
| EP-2968274-A1 | MEROPENEM DERIVATIVES AND USES THEREOF | Kala Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2015051030-A2 | STABILIZED POLYPEPTIDES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-04-09 | — | — | WO | disclosed |
| WO-2014197313-A2 | NOVEL COMPOUNDS AND USES THEREOF | KALA PHARMACEUTICALS, INC. (US) | 2014-12-11 | — | — | WO | disclosed |
| WO-2014144285-A1 | MEROPENEM DERIVATIVES AND USES THEREOF | KALA PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-2367798-A2 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Cambria Pharmaceuticals, Inc. (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20110230551-A1 | WITHAFERIN A ANALOGS AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH | 2011-09-22 | — | — | US | disclosed |
| WO-2010059241-A2 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CAMBRIA PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230551-A1 | WITHAFERIN A ANALOGS AND USES THEREOF | CYP51A1, HASPIN, NFATC1 | PTGS1 1181/4885PTGS2 1129/4885PKM 4772/4885 |
| US-20230192610-A1 | BIOMOLECULE-POLYMER-PHARMACEUTICAL AGENT CONJUGATES FOR DELIVERING THE PHARMACEUTICAL AGENT | MUC1, APOB, PLTP | PTGS1 4220/4885PTGS2 3942/4885PKM 2564/4885 |
| US-12084415-B2 | Biomolecule-polymer-pharmaceutical agent conjugates for delivering the pharmaceutical agent | MUC1, APOB, PLTP | PTGS1 4220/4885PTGS2 3942/4885PKM 2564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.